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Between January 2004 and February 2006, 109 patients after intentionally curative surgery for oesophageal or gastric cardia cancer
were randomised to standard follow-up of surgeons at the outpatient clinic (standard follow-up; n¼55) or by regular home visits of a
specialist nurse (nurse-led follow-up; n¼54). Longitudinal data on generic (EuroQuol-5D, European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30) and disease-specific quality of life (EORTC QLQ-OES18), patient satisfaction and costs
were collected at baseline and at 6 weeks and 4, 7 and 13 months afterwards. We found largely similar quality-of-life scores in the
two follow-up groups over time. At 4 and 7 months, slightly more improvement on the EQ-VAS was noted in the nurse-led
compared with the standard follow-up group (P¼0.13 and 0.12, respectively). Small differences were also found in patient
satisfaction between the two groups (P¼0.14), with spouses being more satisfied with nurse-led follow-up (P¼0.03). No differences
were found in most medical outcomes. However, body weight of patients of the standard follow-up group deteriorated slightly
(P¼0.04), whereas body weight of patients of the nurse-led follow-up group remained stable. Medical costs were lower in the nurse-
led follow-up group (h2600 vs h3800), however, due to the large variation between patients, this was not statistically significant
(P¼0.11). A cost effectiveness acceptability curve showed that the probability of being cost effective for costs per one point gain in
general quality-of-life exceeded 90 and 75% after 4 and 13 months of follow-up, respectively. Nurse-led follow-up at home does not
adversely affect quality of life or satisfaction of patients compared with standard follow-up by clinicians at the outpatient clinic. This
type of care is very likely to be more cost effective than physician-led follow-up.
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Approximately 400000 patients per year are diagnosed worldwide
with oesophageal cancer, which makes this malignancy the eight
most common cancer (Bollschweiler et al, 2001). The incidence of
oesophageal cancer has risen remarkably over the past two decades
in the Western world, due to a marked increase in the incidence of
adenocarcinoma (Devesa et al, 1998; Botterweck et al, 2000).
Despite recent advances in the curative treatment of oesophageal
cancer (Stein and Siewert, 2004), less than 50% of patients have
operable disease at presentation.
Surgery for oesophageal cancer is often accompanied by
significant morbidity (Zieren et al, 1996; Baba et al, 1997; McLarty
et al, 1997; Blazeby et al, 2000; De Boer et al, 2000, 2004; Brooks
et al, 2002; Fagevik Olsen et al, 2005; Viklund et al, 2006). It has
been reported that approximately 30% of patients will develop
recurrent cancer within the first year after oesophageal resection.
For these patients, the prognosis is dismal and palliation of
symptoms is usually the only treatment option (Ando et al, 2000).
Counselling and treatment of physical problems are important
issues during follow-up. In addition, patients may need reassur-
ance and emotional support during follow-up visits (Bernhard and
Hurny, 1998; van ‘t Spijker, 2001).
The role of nurses in patient care has expanded (Worster et al,
2005). Nurses have increasingly become involved in tasks and
procedures previously performed by physicians (Wright, 1997;
Laurant et al, 2005). One area of nurses’ involvement is the
development of nurse-led services in cancer care (Loftus and
Weston, 2001; Cox and Wilson, 2003). We recently performed the
SIREC trial, in which 209 patients were randomised to single dose
(12Gy) brachytherapy or stent placement (Homs et al, 2004). In
this study, patients were prospectively followed by home visits of
specialised research nurses. These nurses were specifically trained
to support patients with incurable oesophageal cancer. They
assisted patients with filling out questionnaires on quality of life,
and, as a not foreseen effect, the nurses were also found to play an
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simportant role in giving advice and support to these patients
(unpublished results). Therefore, we proposed that home visits by
specialised nurses could be an alternative to regular outpatient
clinic visits for patients who have undergone surgical treatment for
oesophageal cancer. In this trial, we compared follow-up at the
outpatient clinic with follow-up by home visits of a specialist nurse
with respect to health-related quality of life (HRQoL), patient
satisfaction and costs.
MATERIALS AND METHODS
Study population
We randomised patients 3 weeks after hospital discharge following
intentionally curative surgery for oesophageal or gastric cardia
cancer to standard follow-up at the outpatient clinic or home visits
by a specialist nurse (nurse-led follow-up). Patients were excluded
if they were shown to have irresectable cancer during intended
oesophagectomy, if they were admitted to a nursing home after
hospital discharge or if they had insufficient knowledge of the
Dutch language (to fill out the questionnaires). Between January
2004 and February 2006, 120 consecutive patients were eligible to
enter the trial. As 11 patients refused to participate, 109 patients
were finally randomised to standard follow-up by a surgeon at the
outpatient clinic (n¼55) or home visits performed by a specialised
nurse (n¼54) (Figure 1). The major reason for unwillingness to
participate was a preference for follow-up at the outpatient clinic
by a physician (n¼9). Two patients of the standard follow-up
group were lost to follow-up. One patient was admitted to a
nursing home during follow-up, and the other patient preferred to
be evaluated in a general hospital nearby his home.
The study was approved by the Central Committee on Research
Involving Human Subjects in the Netherlands. Participating
centres included one university hospital (Erasmus MC – University
Medical Center Rotterdam; n¼105), and one general hospital
(Reinier de Graaf Hospital Delft; n¼4). All patients gave written
informed consent for randomisation. Patients were stratified for
radiation and/or chemotherapy before surgery, and for hospital.
Randomisation was performed centrally by the Trial Office of
the Department of Oncology, Erasmus MC Rotterdam, using
computer-generated lists.
Interventions
Nurse-led follow-up was performed by home visits of a specialist
nurse with more than 10 years experience in oncological care.
Didactic training included a syllabus on diagnosis and treatment of
oesophageal and gastric cardia cancer, potential problems after
oesophageal resection and medical-legal issues. Aspects to
consider during follow-up were derived from a previous explora-
tory study (Verschuur et al, 2006). Standard follow-up was
performed by a group of two senior surgeons at the outpatient
clinic of the Erasmus MC Rotterdam and one senior surgeon at the
Reinier de Graaf Hospital Delft. The duration of follow-up visits
was recorded in both groups.
The participating surgeons as well as the specialist nurse filled
out standardised case record forms. Case record forms include a
list of items for assessment of patients during the follow-up visits,
such as experienced problems and symptoms, body weight and the
ability to eat and/or swallow using a dysphagia score (Ogilvie et al,
1982), graded as: 0¼ability to eat a normal diet; 1¼ability to eat
some solids; 2¼ability to eat some semisolids only; 3¼ability to
swallow liquids only; 4¼complete dysphagia.
During follow-up, all patients were discussed during 4-weekly
multidisciplinary meetings in the participating hospitals. Sched-
uled follow-up visits for both follow-up groups were 6 weeks, and
3, 6, 9 and 12 months after randomisation.
Study end points
The primary outcome of the study was HRQoL; secondary
outcomes included patient satisfaction and costs.
Fulfilled in-/exclusion
criteria (n=120)
Refused to participate (n=11)
Randomised
(n=109)
Allocated to usual follow-up
(n=55)
Received allocated intervention
(n=55)
Lost to follow-up (n=2)
Analysed (n=55)
Excluded from analyses (n=0)
Allocated to nurse-led follow-up
(n=54)
Received allocated intervention
(n=54)
Lost to follow-up (n=0)
Analysed (n=54)
Excluded from analyses (n=0)
Figure 1 Flow chart of the study comparing standard follow-up with nurse-led follow-up in 109 patients after oesophageal cancer surgery.
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sHealth-related quality of life was assessed using the EuroQol-5D
(Dolan, 1997) including a self-classifier with five items and a visual
analogue scale (EQ-VAS) for the measurement of overall self-rated
health, the oesophageal cancer-specific European Organization for
Research and Treatment of Cancer (EORTC) QLQ-OES18 ques-
tionnaire (Blazeby et al, 2003) and the generic EORTC QLQ-C30
questionnaire (Aaronson et al, 1993). The EQ-5D assesses five
dimensions including mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. For each dimension, patients
mark one of three levels of severity (level 1¼no problems, level
2¼some/moderate problems, level 3¼severe/extreme problems),
which subsequently can be classified into one of 243 (3
5) possible
health status profiles. Each profile can be linked to an index score
based on empirical preferences for health status from an English
population (Dolan, 1997). The EQ-VAS is a 20cm vertical visual
analogue scale on which patients are asked to rate their overall
health between 0 (‘worst imaginable health state’) and 100 (‘best
imaginable health state’). The EORTC QLQ-OES18 incorporates
five multi-item scales (dysphagia, eating, deglutition, indigestion,
pain) and four single symptoms (having a dry mouth, troublesome
taste, coughing and talking). The EORTC QLQ-C30 incorporates
nine multi-item scales: five functional scales (physical, role,
emotional, cognitive, social), three symptom scales (fatigue,
nausea/vomiting, pain) and a global health/quality-of-life scale.
We developed a satisfaction questionnaire for patients as well as
their spouses, as no specific validated questionnaire was available.
We focused on expectations of patients, information and advice,
emotional support and overall satisfaction. Replies related to
satisfaction were rated as very satisfied, satisfied, dissatisfied and
very dissatisfied. Patients were asked to rate their overall
satisfaction on a scale from 0 to 10. A panel of three experts (a
methodologist, a gastroenterologist and a gastrointestinal surgeon)
had established the face validity of the questionnaire. Before its use
in this trial, the questionnaire was validated in five patients.
Medical costs included costs of follow-up visits, intramural care,
diagnostic procedures, additional treatments (for example, pallia-
tive treatment) and extramural care. We estimated full cost prices
on the basis of real resource use from a societal perspective.
Volumes of care were recorded for all patients and unit prices were
determined with the micro costing method (Gold et al, 1996). All
costs are reported in euro for the year 2006 in the Netherlands.
Data collection
Patients were asked to complete HRQoL questionnaires before
randomisation, and at 4, 7 and 13 months after randomisation. The
questionnaire assessing patient satisfaction was filled out 7 months
after randomisation. After reminders, patients returned 135 of the
141 (96%) questionnaires in the standard follow-up group and 144
of 147 (98%) questionnaires in the nurse-led follow-up group. The
use of medical services and palliative treatment (if indicated) was
assessed during follow-up visits 6 weeks, and 3, 6, 9 and 12 months
after randomisation.
Statistics
Analyses were performed on an intention-to-treat basis. We
calculated that two groups of 50 patients would be sufficient for
a difference of approximately 0.56 standard deviation on the
standardised EuroQol-5D, with a two-sided a¼5%, and a power of
80%.
Quality-of-life scores were evaluated with analysis of repeated
measurements (Fairclough, 2002). For each scale, a model was
fitted that estimated levels for all six combinations of time and
follow-up group. Time and follow-up group were included as fixed
factors, whereas patients were the random factor. An ANOVA test
was performed for interaction between time and follow-up group.
Confidence intervals around the six levels were computed based on
the model. For easier interpretation of differences between
randomised groups, we also estimated the average differences over
time for scales on which no clear interaction was noted (P40.10),
using analysis of covariance with the baseline value as covariate.
Clinical outcome and patient satisfaction were expressed as mean-
s±standard deviation (s.d.) and as medians, as appropriate. Body
weight was evaluated with analysis of repeated measurements.
Survival rates were determined using the Kaplan–Meier method. As
cost data typically have a highly skewed distribution, we used non-
parametric bootstrap techniques to derive a P-value for the
differences in distribution of the direct medical costs (Thompson
and Barber, 2000). Cost effectiveness was further analysed with
acceptability curves. These curves showed the probability that one
follow-up strategy was more cost effective compared with the other
strategy for a range of values that decision makers might be willing
to pay for a one point gain in the EQ-VAS for quality of life at 4 and
13 months (Fenwick et al, 2006).
A P-value o0.05 was considered statistically significant. Calcula-
tions were performed with SPSS version 11.5 (SPSS Inc., Chicago, IL,
USA), and S-plus 6.0 (Insightful Inc., Seattle, WA, USA).
RESULTS
Patient characteristics and functional outcome
The two patient groups were similar with respect to clinical
characteristics (Table 1). The surgical procedure was a transhiatal
oesophagectomy in 84 (77%) patients and a transthoracic
oesophagectomy in 25 (23%). Postoperative complications at the
intensive care unit included predominantly pulmonary complica-
tions (standard follow-up n¼18 (33%) vs nurse-led follow-up
n¼17 (32%), P¼0.89) and anastomotic leakage (standard follow-
up n¼3 (6%) vs nurse-led follow-up n¼3 (6%), P¼0.98).
The median duration was significantly shorter in the standard
Table 1 Clinical characteristics of 109 patients randomised to standard
follow-up or nurse-led follow-up after oesophageal cancer surgery
Standard
follow-up
(N¼55)
Nurse-led
follow-up
(N¼54)
Mean age; years±s.d. 61±76 1 ±9
Gender; no. of patients (%)
Male 41 (75) 40 (74)
Female 14 (25) 14 (26)
Type of reconstruction; no. of patients (%)
Gastric tube interposition 54 (98) 54 (100)
Colon interposition 1 (2) 0 (0)
Tumour histology; no. of patients (%)
Adenocarcinoma 42 (76) 40 (74)
Squamous cell carcinoma 12 (22) 13 (24)
Other 1 (2) 1 (2)
Prior radiation and/or chemotherapy; no. of
patients (%)
Total 17 (31) 14 (26)
Chemotherapy 12 6
Radiation and chemotherapy 5 8
Pathological staging; no. of patients (%)
Stage 0–I 15 (27) 13 (24)
Stage II 19 (34) 12 (22)
Stage III 8 (15) 13 (24)
Stage IV 13 (24) 16 (30)
Median dysphagia score at baseline 0 0
P¼NS for all items.
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sfollow-up group than in the nurse-led follow-up group (11 vs
43min, Po0.01, M–W test).
All patients experienced a change in food intake pattern,
resulting in the distribution of more and smaller meals over the
day. During follow-up, the majority of patients were able to eat a
normal diet or ate solid food with some difficulty (dysphagia score
0–1). No differences were found in dysphagia scores between the
two follow-up groups during follow-up (P¼0.20). Mean body
weight of patients of the standard follow-up group deteriorated
during the first year after surgery (from 73.2kg at randomisation
to 71.2 and 69.6kg at 6 and 12 months, respectively; P¼0.04),
whereas mean body weight in the nurse-led follow-up group
remained stable or slightly increased (74.5, 74.2, 75.5kg, respec-
tively; P¼0.19). We found no differences in physical problems
such as pain (standard follow-up vs nurse-led follow-up: n¼10
(18%) vs n¼9 (17%), 6-month visits; P¼0.72, and n¼5 (9%) vs
n¼5 (9%), 12-month visits; P¼0.74) or defecation problems
(n¼8 (15%) vs n¼6 (11%), 6-month visits; P¼0.54), and n¼0
(0%) vs n¼4 (7%), 12-month visits; P¼0.13). If specific
symptoms and medical problems occurred, the specialist nurse
referred patients to the outpatient clinic for medical evaluation
(n¼21, 39%). Thirty-two (28%) patients (standard follow-up
n¼15 (15%) vs nurse-led follow-up n¼17 (31%); P¼0.63)
developed dysphagia (score 2–4), and these patients needed one
or more (mean 3±2, range 1–8) dilations of a benign anastomotic
stricture. Eleven (20%) patients of the nurse-led follow-up group
and 16 (29%) patients of the standard follow-up group were
diagnosed with recurrent loco regional tumour and/or metastases
at 1-year survival (P¼0.50). Of these, nine (33%) had palliative
chemotherapy, whereas five (19%) patients were treated with
external beam radiation therapy. Fourteen (13%) patients, seven in
each follow-up group (P¼0.41), died within the first year after
surgery.
Health-related quality of life
For all patients, the scores on the EuroQol significantly improved
during follow-up, including the EQ-5D index (Po0.001) and the
EQ-VAS for overall self-rated health (Po0.001). At 4 and 7
months, slightly more improvement on the EQ-VAS was noted for
the nurse-led group than the standard follow-up group (mean
scores 74 vs 69, P¼0.13 and 0.12, respectively, Table 2 and
Figure 2).
Mean EORTC QLQ-OES18 and QLQ-C30 scale scores were
similar for patients of the standard follow-up group and those of
the nurse-led follow-up group over time. Although not significant,
better scores were found in the dysphagia scale (at 7 months, QLQ-
OES18) in favour of the standard follow-up group (P¼0.11).
Similarly, in the nurse-led follow-up group, slightly better scores
were found in the deglutition scale (at 13 months, QLQ-OES18;
P¼0.14), the emotional (at 4 months, QLQ-C30; P¼0.13) and
cognitive functioning scales (at 7 and 13 months, QLQ-C30;
P¼0.12 and 0.11, respectively), and global health status (at 7
months, QLQ-C30; P¼0.12) (Table 2). For the group as a whole, a
significant improvement was found in the dysphagia, eating, and
indigestion scale scores (QLQ-OES18), and the fatigue, physical,
role, cognitive and social functioning scales, and in global health
(QLQ-C30).
Patient satisfaction
Mean overall patient satisfaction was 8.3±1.2 for the nurse-led
follow-up group compared with 7.9±1.2 for the standard follow-
up group at 7 months (P¼0.14). Spouses of patients in the nurse-
led follow-up group were more satisfied with the follow-up visits
then those in the standard follow-up group (mean overall rating:
8.1 vs 7.4; P¼0.03). Patients and spouses in the standard follow-up
group more often indicated that the visits did not fulfil their
expectations (P¼0.04 and 0.03, respectively). They frequently
stated that they had expected a systematic follow-up schedule with
diagnostic tests and/or procedures for the early detection of
recurrent malignancy. As compared with the standard follow-up
group, patients and spouses of the nurse-led follow-up group
received more often advice regarding disease management
(patients: n¼45 vs n¼37, P¼0.04 and spouses: n¼27 vs
n¼20; P¼0.03). In addition, spouses of the nurse-led follow-up
group more often experienced that they had an opportunity to ask
questions (P¼0.06).
Costs
Costs of nurse-led follow-up visits were significantly lower than
those of standard follow-up visits (h234 vs h503; Po0.001,
Table 3). Costs for intramural care during follow-up were the
highest for both types of follow-up, but differences were not
statistically significant (nurse-led follow-up h1477 vs standard
follow-up h2277; P¼0.19). Mean hospital stay was 8.9 days for
nurse-led follow-up vs 17.8 days for standard follow-up (P¼0.07).
Costs were similar in both follow-up groups for diagnostic
procedures (nurse-led follow-up h588 vs standard follow-up
h689; P¼0.34), additional treatments (h182 vs h255; P¼0.29)
and extramural care (h111 vs h74; P¼0.97). Total costs were
substantially lower for nurse-led follow-up than for standard
follow-up (h2592 vs h3789), however, due to the large variation,
this difference was not statistically significant (P¼0.11).
There was a 91% probability that nurse-led follow-up was
cost-effective compared to standard follow-up, discarding quality-
of-life effects (willingness to pay h0, Figure 3). The 4-month
EQ-VAS scores were relatively high for nurse-led follow-up (mean
improvement 14 vs 9 points, Table 2), resulting in a 98%
probability that nurse-led follow-up was cost effective compared
with standard follow-up at a relatively low cost of h500 per point
improvement in EQ-VAS (Figure 3). The 13-month EQ-VAS scores
for nurse-led follow-up had deteriorated slightly, whereas the
scores for standard follow-up remained stable (mean improvement
11 vs 9 points). Therefore, a decision maker willing to pay h4000 or
more for a one point gain on the EQ-VAS would find nurse-led
follow-up cost effective with a probability of 76% (Figure 3).
DISCUSSION
Results from this study show that nurses can well perform follow-
up of patients at home after upper gastrointestinal cancer surgery.
Nurse-led follow-up had some small, statistically nonsignificant,
positive effects on quality of life and satisfaction of patients and
spouses. In addition, this follow-up strategy was most likely to be
cost effective compared with standard follow-up.
As far as we are aware, no previous studies have reported about
follow-up of cancer patients by home visits, although nurses have
increasingly become involved in the care of patients with
malignancies (Loftus and Weston, 2001). Results from this study
are in line with findings in other studies, in which nurse-led
follow-up of patients undergoing pelvic radiotherapy (Faithfull
et al, 2001) or with lung cancer (Moore et al, 2002) was also
reported to be effective with regard to assessment of symptoms,
patient satisfaction and costs.
For some disease-specific or generic quality-of-life scores,
slightly more improvement was noted for the nurse-led than the
standard follow-up group. We found no differences in quality-of-
life scores over time in the two follow-up groups. In agreement
with other studies, the largest improvement in quality of life was
seen during the first months after surgery (Zieren et al, 1996;
De Boer et al, 2000, 2004; Brooks et al, 2002). It has previously
been reported that some symptoms, such as early satiety, fatigue
and diarrhoea, still persist in patients 2 years after oesophageal
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sresection and without evidence of tumour recurrence (De Boer
et al, 2000; Fagevik Olsen et al, 2005). Indeed, we found that
nausea/vomiting, diarrhoea and fatigue were still present 13
months after surgery. These results confirm that a relatively
extended period is required for patients to recover from
oesophageal or gastric cancer surgery and to adjust to the new
anatomical situation.
Assessment of patient satisfaction may provide information
about the extent to which patients’ needs and expectations are
addressed (Bredart et al, 2005). We found no differences in patient
satisfaction between the nurse-led follow-up group and standard
follow-up group, despite the fact that the duration of follow-up was
longer in the nurse-led follow-up group than in the standard
follow-up group (median: 43 vs 11min). However, spouses in the
nurse-led follow-up group were more satisfied with this new type
of care compared with those of the standard follow-up group.
Northouse et al (2000) found that spouses more often reported
emotional distress and experienced less social support than
patients. Health professionals should include family caregivers in
Table 2 Health-related quality of life (HRQoL) during follow-up of 109 patients after oesophageal cancer surgery
Mean baseline
score (s.d.)
Mean score at 4 months
follow-up (s.d.)
Mean score at 7 months
follow-up (s.d.)
Mean score at 13 months
follow-up (s.d.)
Scale
Standard
follow-up
Nurse-led
follow-up P-value
Standard
follow-up
Nurse-led
follow-up P-value
Standard
follow-up
Nurse-led
follow-up P-value
Standard
follow-up
Nurse-led
follow-up P-value
EuroQol (100¼best)
EQ-5D 70 (0) 66 (0) 0.44 79 (0) 76 (0) 0.56 77 (0) 76 (0) 0.96 74 (0) 78 (0) 0.58
EuroQol VAS scale 60 (5) 60 (5) 0.89 69 (5) 74 (6) 0.13 69 (6) 74 (6) 0.12 69 (7) 71 (6) 0.66
EORTC QLQ-OES18 (0¼best)
Dysphagia scale 17 (7) 17 (7) 0.96 12 (7) 11 (7) 0.83 8 (7) 11 (7) 0.11 11 (9) 14 (9) 0.34
Eating scale 34 (10) 36 (10) 0.67 28 (10) 25 (11) 0.60 23 (11) 24 (11) 0.82 28 (13) 27 (11) 0.85
Deglutition scale 17 (8) 13 (8) 0.30 14 (9) 17 (9) 0.40 14 (9) 14 (9) 0.99 9 (11) 15 (10) 0.14
Indigestion scale  5 (11)  2 (11) 0.55 1 (11) 4 (11) 0.44 6 (11) 4 (12) 0.67 2 (14) 4 (12) 0.64
Pain scale 12 (5) 10 (5) 0.60 11 (5) 9 (6) 0.53 15 (6) 12 (6) 0.45 9 (7) 9 (6) 0.88
Single items (0¼best)
Having dry mouth 28 (13) 33 (14) 0.42 15 (14) 10 (15) 0.32 17 (15) 15 (15) 0.56 24 (19) 17 (16) 0.22
Troublesome taste 21 (13) 26 (12) 0.29 13 (13) 9 (13) 0.46 11 (14) 10 (14) 0.94 15 (17) 7 (14) 0.16
Troublesome coughing 33 (13) 30 (13) 0.63 23 (14) 16 (14) 0.17 23 (15) 16 (15) 0.21 21 (19) 13 (15) 0.19
Troublesome talking 22 (12) 21 (12) 0.77 13 (13) 8 (13) 0.38 15 (14) 10 (14) 0.39 13 (17) 11 (14) 0.73
EORTC QLQ-C30
Functional scales (100¼best)
Physical functioning 67 (7) 64 (7) 0.44 81 (8) 80 (8) 0.83 82 (8) 81 (8) 0.79 78 (9) 82 (8) 0.45
Role functioning 46 (15) 45 (16) 0.94 69 (16) 70 (16) 0.84 71 (17) 73 (17) 0.75 69 (20) 76 (17) 0.30
Emotional functioning 79 (10) 79 (10) 0.89 76 (10) 83 (11) 0.13 77 (11) 80 (11) 0.51 79 (12) 80 (11) 0.83
Cognitive functioning 78 (9) 80 (9) 0.63 83 (10) 85 (10) 0.65 77 (10) 84 (10) 0.12 76 (12) 84 (10) 0.11
Social functioning 69 (11) 74 (11) 0.23 80 (11) 82 (11) 0.58 80 (12) 84 (12) 0.40 78 (14) 85 (12) 0.15
Global health status 61 (6) 61 (7) 0.85 73 (7) 77 (7) 0.26 72 (7) 78 (7) 0.12 71 (9) 73 (7) 0.49
Symptom scales (0¼best)
Fatigue scale 52 (12) 53 (12) 0.78 32 (13) 32 (13) 0.92 34 (13) 32 (13) 0.70 35 (15) 27 (13) 0.14
Nausea/vomiting scale 22 (9) 21 (9) 0.85 21 (10) 13 (10) 0.07 17 (10) 12 (10) 0.30 17 (12) 16 (11) 0.80
Pain scale 18 (11) 24 (11) 0.87 13 (11) 15 (12) 0.74 18 (12) 18 (12) 0.78 22 (14) 22 (12) 0.24
100
80
60
40
20
0
02468 1 0 12
Months
Overall P = 0.28
Euroquol visual analogue scale: self-rated health
Figure 2 Quality of life sore after usual follow-up (n¼55) or nurse-led
follow-up (n¼54) after oesophageal cancer surgery from the EQ-VAS.
The graph shows the mean scores with 95% confidence intervals of the
scale during follow-up. (--&-- nurse-led; —’— usual).
Table 3 Mean health-care use and costs (in h) per patient during follow-
up after oesophageal cancer surgery
Cost category
Standard
follow-up
(n¼55)
Nurse-led
follow-up
(n¼54) P-value
a
Follow-up visits 503 234 o0.001
Total intramural care
b 2277 1477 0.19
Total diagnostic procedures
c 689 588 0.34
Additional treatment
d 255 182 0.29
Extramural care
e 74 111 0.97
Total costs per patient 3798 2592 0.11
aDerived from 2000 bootstrap samples drawn with replacement.
bCosts include
hospital stay and extra visits to outpatient clinic.
cCosts include diagnostic procedures,
for example, endoscopy, X-ray, CT-scan.
dCosts include additional treatment, for
example, chemotherapy, radiation therapy.
eCosts include, for example, visits to the
general practitioner.
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splanned programs of care. In addition, they should support both
patients and spouses, not only because both have legitimate needs
for support, but also because role adjustment problems in spouses
may negatively affect the long-term adjustment of patients
(Northouse et al, 2000). The results of our study support this.
If specific symptoms and medical problems occurred in the
nurse-led follow-up group, patients were referred to the outpatient
clinic for evaluation (n¼21, 39%). We found no differences in
occurrence of recurrent tumour growth and/or metastases, and in
survival between both follow-up groups. This suggests that
patients of the nurse-led follow-up group were adequately referred
to a medical specialist for evaluation of symptoms and problems
that occurred during follow-up, such as dysphagia or suspicion of
recurrent malignancy. In the future, it may well be that curative
treatment options for recurrent or metastatic disease will become
available. If this is the case, a more active approach to detect
recurrent or metastatic oesophageal cancer will most likely be part
of the follow-up protocol of patients with resected oesophageal
cancer.
A l t h o u g ht h em a j o r i t yo fp a t i e n t sw e r ea b l et oe a tan o r m a ld i e to r
solid food with some difficulty, body weight of patients of the standard
follow-up group deteriorated slightly (P¼0.04), whereas body weight
of patients of the nurse-led follow-up group remained stable. This can
probably be explained by the fact that disease management, such as
advice on food intake and diet, routinely was part of the follow-up
strategy in patients of the nurse-led follow-up group and was probably
less explicitly performed in the standard follow-up group.
It is remarkable that economic implications of involvement of
nurses in the oncological practice have only been evaluated in a
few studies (Wallace et al, 1999; Helgesen et al, 2000; Faithfull et al,
2001; Basnyat et al, 2002; Moore et al, 2002; Niv and Niv, 2005). We
found that costs of intramural care were substantially lower in the
nurse-led follow-up group, although not statistically significant.
Nurse-led followed patients were less frequently admitted or
visited the outpatient clinic, which translated in a reduced use of
hospital-related medical services compared with the standard
follow-up group. In addition, nurse-led follow-up may reconfigure
care to make it more responsive to individual needs, and reduce
the burden of unnecessary hospital visits and investigations for
patients. Although total cost were not significantly different,
acceptability curves showed that nurse-led follow-up of patients
after oesophageal or gastric cardia cancer surgery was very likely a
cost-effective strategy.
A limitation of this study is the limited sample size. The study
was designed to test for a major difference in HRQOL (0.56 s.d.,
requiring 4100 patients). The test was two-sided, allowing for
doctors to be better or worse than the nurses. To more precisely
investigate nurse-led follow-up of patients after upper gastro-
intestinal cancer surgery, further research is needed.
In conclusion, nurse-led follow-up at home does not adversely
affect quality of life or satisfaction of patients compared with
follow-up by clinicians at the outpatient clinic. Although not
significant, some quality-of-life scores were in the advantage of the
nurse-led follow-up group. In addition, this type of care is most
likely to be more cost effective. We speculate that this type of
follow-up could also be an attractive alternative to standard follow-
up of patients with other types of cancer, particularly in patients in
whom no curative treatment option is available for recurrent or
metastastic malignancy, for example, pancreatic cancer. In
addition, a nurse-led service at home may help to reduce waiting
lists in hospitals and/or reduce the workload of physicians.
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